Status:
UNKNOWN
Xience/Promus for Long Coronary Lesion Registry
Lead Sponsor:
Society for Advancement of Coronary Intervention Research
Conditions:
Long Coronary Artery Disease
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
The utilization of everolimus-eluting coronary stents in a coronary artery diseases is effective in reducing both repeat revascularization and major adverse cardiac events within two year follow-up. T...
Eligibility Criteria
Inclusion
- Age ≥20 years and are able to undergo CABG
- Females who are not pregnant
- Patients who present with angina symptoms or myocardial ischemia
- Patients available for post-procedural observation and coronary angiography at 24 months
- Patients who have signed patient informed consent
- Lesion length is more than 30mm
- De novo lesion or non-stented restenosed lesion
Exclusion
- Patients contraindicated for antiplatelet therapy or anticoagulant therapy
- Patients with significant allergic reaction to contrast medium
- Chronic total occlusion
- Lesion with TIMI0
- Patients with chronic renal failure (SCr\>3.0mg/dl) -
Key Trial Info
Start Date :
February 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT01147237
Start Date
February 1 2010
End Date
December 1 2012
Last Update
June 22 2010
Active Locations (31)
Enter a location and click search to find clinical trials sorted by distance.
1
Japanese Red Cross Nagoya Daiichi Hospital
Nagoya, Aichi-ken, Japan
2
Toyohashi Heart Center
Toyohashi, Aichi-ken, Japan, 4418530
3
Higashi Cardiovascular clinic
Toyohashi, Aichi-ken, Japan
4
Hiraka General Hospital
Yokote, Akita, Japan